| CAS NO: | 55778-02-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 290.36 |
|---|---|
| Formula | C18H18N4 |
| CAS No. | 55778-02-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 30 mg/mL (103.3 mM) |
| Water:<1 mg/mL | |
| Ethanol:<1 mg/mL | |
| Other info | Chemical Name: N,N'-(1,4-phenylenebis(methylene))bis(pyridin-2-amine) InChi Key: KBVFRXIGQQRMEF-UHFFFAOYSA-N InChi Code: InChI=1S/C18H18N4/c1-3-11-19-17(5-1)21-13-15-7-9-16(10-8-15)14-22-18-6-2-4-12-20-18/h1-12H,13-14H2,(H,19,21)(H,20,22) SMILES Code: C1(CNC2=NC=CC=C2)=CC=C(CNC3=NC=CC=C3)C=C1 |
| Synonyms | WZ811; WZ-811; WZ 811 |
| In Vitro | In vitro activity: WZ811 is a highly potent competitive antagonist of CXCR4. WZ811 is effective in counteracting SDF-1 on cAMP reduction at doses as low as a few nanomoles. WZ811 blocks SDF-1-mediated invasion with EC50 of 5.2 NM. Cell Assay: In the cAMP assay, WZ811 reduces the effect on cAMP caused by 150ng/ml SDF-1 significantly. It also blocks the SDF-1 induced Matrigel invasion with EC50 value of 5.2nM. Since CXCR4 is involved in the pathogeneses of a wide range of infectious, inflammatory and other diseases, WZ811 is developed for the treatment of various CXCR4-related diseases. It is reported to have weak anti-HIV activity in cell culture. |
|---|---|
| In Vivo | WZ811 (40 mg/kg, p.o.) blocks the lymphocytic leukemia cells growth on mouse xenograft models, and inhibits CXCR4/PI3K/AKT signaling pathway in mouse xenograft model of lymphocytic leukemia |
| Animal model | Mice |
| Formulation & Dosage | 40 mg/kg, p.o. |
| References | J Med Chem. 2007 Nov 15;50(23):5655-64. |
m.cnreagent.com